- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
According to the WHO, about 2.3 million people are co-infected with HIV and the hepatitis C virus (HCV). Moreover, there were an estimated 1.75 million new hepatitis C virus (HCV) infections worldwide in 2015. HCV usually presents only mild symptoms, if any, until it is at an advanced stage, thereby making it difficult to recognize the disease early.
With the 2016 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, WHO updated and launched new policy recommendations on the clinical and service delivery aspects of HIV treatment and care, and raised the bar to treat all PLHIV (Treat All). WHO has worked with countries to ensure uptake and implementation of these recommendations in support of the to the 90-90-90 targets.
This fact sheet present data for 194 WHO Member States – including 139 low- and middle-income countries – and 35 Fast-Track countries, respectively through November 2017.
The International Council of AIDS Service Organizations (ICASO) developed this brief to provide the HIV community with current information and analysis of new and updated clinical data on the effectiveness of antiretroviral therapy (ART) in preventing HIV transmission to sexual partners of people living with HIV. While the health benefits of treatment will always be the primary purpose of ART, it is vital that the secondary benefits to people living with HIV and their sexual partners be fully understood and communicated.
Keywords: HIV, ART, transmission, advocacy, prevention
The advent of point-of-care (POC) Early Infant Diagnosis (EID) technologies is a breakthrough that creates the opportunity to increase coverage of EID testing. It will allow same-day test results and enable the initiation of earlier treatment, as well as address some of the key limitations of conventional EID networks – in particular long turnaround times for tests and high rates of loss to follow up.
The hepatitis C virus (HCV) has long since been a neglected disease, given long latency periods before any chronic illness manifests, and the low cure rate and numerous side effects of the pegylated interferon-ribavirin treatment (hereinafter PEGINF). However, of late, given the development of revolutionary drugs called direct-acting antivirals (DAAs) that can cure the disease in as little as 8 weeks, international interest, and with it, international financial investment, has peaked.
The world has embraced the UNAIDS 90–90–90 treatment target, whereby 90% of people living with HIV know their HIV status, 90% of people who know their HIV-positive status are accessing antiretroviral treatment, and 90% of people on treatment have suppressed viral loads. By reaching the 90–90–90 treatment target by 2020, the world will be firmly on track towards ending the AIDS epidemic by 2030.
Keywords: HIV, treatment, HLM2016AIDS, ART, Fast-Track
In 2000, when the International AIDS Conference was last held in Durban, South Africa, a basic antiretroviral (ARV) regimen cost over US$10,000 per person per year (PPPY), multilateral programmes funding the fight against HIV, TB, and malaria did not exist, and many donors – such as the US government – had yet to provide a single dollar for antiretroviral treatment in resource-limited countries.
Data from the DOH - Epidemiology Bureau shows that only 44o/o of allpeople diagnosed with HIV from 2010 to 2015 were started on Anti-Retroviral Therapy (ART). Based on the 2013 external evaluation of the health sector's response to HIV in the Philippines, long turn-around time of confirmatory HIV testing is one of the identified barriers for prompt referral and management. In the interim, this memorandum shall ensure linkage to care of clients with reactive HIV screening test to immediately be assessed by Treatment hubs, satellite treatment hubs and HIV primary care clinics in order to provide early treatment and management.
This year World Antibiotic Awareness Week will be held from 14 to 20 November 2016. The campaign aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers, policy-makers and the agriculture sector to avoid the further emergence and spread of antibiotic resistance.
The global HIV epidemic claimed fewer lives in 2015 than at any point in almost two decades, and fewer people became newly infected with HIV than in any year since 1991. The list of countries on the brink of eliminating new HIV infections among children keeps growing. A massive expansion of antiretroviral therapy (ART) has reduced the global number of people dying from HIV-related causes to about 1.1 million in 2015 – 45% fewer than in 2005. UNAIDS/WHO estimates show that more than 18 million people were receiving ART in mid-2016.